Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

  1. Dimopoulos, M.A.
  2. Opat, S.
  3. D'Sa, S.
  4. Jurczak, W.
  5. Lee, H.-P.
  6. Cull, G.
  7. Owen, R.G.
  8. Marlton, P.
  9. Wahlin, B.E.
  10. Garcia-Sanz, R.
  11. McCarthy, H.
  12. Mulligan, S.
  13. Tedeschi, A.
  14. Castillo, J.J.
  15. Czyz, J.
  16. Fernández de Larrea, C.
  17. Belada, D.
  18. Libby, E.
  19. Matous, J.
  20. Motta, M.
  21. Siddiqi, T.
  22. Tani, M.
  23. Trněný, M.
  24. Minnema, M.C.
  25. Buske, C.
  26. Leblond, V.
  27. Treon, S.P.
  28. Trotman, J.
  29. Chan, W.Y.
  30. Schneider, J.
  31. Allewelt, H.
  32. Patel, S.
  33. Cohen, A.
  34. Tam, C.S.
  35. Show all authors +
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ISSN: 1527-7755

Year of publication: 2023

Volume: 41

Issue: 33

Pages: 5099-5106

Type: Article

DOI: 10.1200/JCO.22.02830 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals